Jeb Keiper, Nimbus CEO

Flush with cash, com­pu­ta­tion­al chem­istry pi­o­neer Nim­bus con­sid­ers next steps. Is an IPO in the fu­ture?

When Bruce Booth helped launch Nim­bus Ther­a­peu­tics back in 2009, it was dif­fi­cult to find co-in­vestors will­ing to back the com­pa­ny’s pi­o­neer­ing com­pu­ta­tion­al chem­istry plat­form. Those were the “lean­er times for the sec­tor,” he said, and the bud­get was tight.

That all end­ed when Gilead inked a mas­sive $1.2 bil­lion NASH deal with Nim­bus in 2016. And the cash keeps flow­ing for the Cam­bridge, MA-based biotech.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.